Literature DB >> 9888485

Survival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients.

A Villa, F Parazzini, G Scarfone, P Guarnerio, G Bolis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9888485

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  3 in total

Review 1.  Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy.

Authors:  D D Gibbs; M E Gore
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.

Authors:  Shin Nishio; Noriyuki Katsumata; Koji Matsumoto; Hiroshi Tanabe; Kan Yonemori; Tsutomu Kouno; Chikako Shimizu; Masashi Ando; Toshiharu Kamura; Takahiro Kasamatsu; Yasuhiro Fujiwara
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-01       Impact factor: 4.553

3.  Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.

Authors:  Sanjay Sharma; Michael H Neale; Federica Di Nicolantonio; Louise A Knight; Pauline A Whitehouse; Stuart J Mercer; Bernard R Higgins; Alan Lamont; Richard Osborne; Andrew C Hindley; Christian M Kurbacher; Ian A Cree
Journal:  BMC Cancer       Date:  2003-07-03       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.